Cardiometabolic development accounts for five trials in this edition, with obesity, peripheral artery disease and pulmonary arterial hypertension driving the strongest activity.
Novo Nordisk opened two major Phase 3 programs comparing next generation obesity assets directly against semaglutide. Amgen is separately testing whether patients already receiving semaglutide or tirzepatide can successfully switch to monthly MariTide.
The largest program is Regeneron’s ROXI PALISADE master protocol, enrolling 7,050 participants to evaluate two Factor XI antibodies in symptomatic peripheral artery disease. VIVUS is also taking extended release tacrolimus into Phase 3 pulmonary arterial hypertension testing.